{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:18Z","timestamp":1788262158731,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00432-019-02894-3","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T15:04:59Z","timestamp":1555340699000},"page":"1589-1599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia"],"prefix":"10.1007","volume":"145","author":[{"name":"the BFORE Study Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Garcia-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Crescenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Mamolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Reisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"2894_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1078155213520261","volume":"21","author":"KR Anderson","year":"2015","unstructured":"Anderson KR, Chambers CR, Lam N, Yau PS, Cusano F, Savoie ML, Sheikh N (2015) Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract 21:19\u201325. \n                    https:\/\/doi.org\/10.1177\/1078155213520261","journal-title":"J Oncol Pharm Pract"},{"key":"2894_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1524-4733.2006.00108.x","volume":"9","author":"M Bharmal","year":"2006","unstructured":"Bharmal M, Thomas J 3rd (2006) Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 9:262\u2013271. \n                    https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00108.x","journal-title":"Value Health"},{"key":"2894_CR3","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851\u20132857. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.66.2866","journal-title":"J Clin Oncol"},{"key":"2894_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/0163278705275341","volume":"28","author":"PS Brucker","year":"2005","unstructured":"Brucker PS, Yost K, Cashy J, Webster K, Cella D (2005) General population and cancer patient norms for the functional assessment of cancer therapy-general (FACT-G). Eval Health Prof 28:192\u2013211. \n                    https:\/\/doi.org\/10.1177\/0163278705275341","journal-title":"Eval Health Prof"},{"key":"2894_CR5","volume-title":"F.A.C.I.T. manual. Manual of the functional assessment of chronic illness therapy (FACIT) scales, v4","author":"D Cella","year":"1997","unstructured":"Cella D (1997) F.A.C.I.T. manual. Manual of the functional assessment of chronic illness therapy (FACIT) scales, v4. Center on Outcomes, Research and Education (CORE). Evanston Northwestern Healthcare, and Northwestern University, Evanston"},{"key":"2894_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","volume":"15","author":"D Cella","year":"2012","unstructured":"Cella D et al (2012) Measuring health-related quality of life in leukemia: the functional assessment of cancer therapy-leukemia (FACT-Leu) questionnaire. Value Health 15:1051\u20131058. \n                    https:\/\/doi.org\/10.1016\/j.jval.2012.08.2210","journal-title":"Value Health"},{"key":"2894_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","volume":"18","author":"J Cortes","year":"2004","unstructured":"Cortes J (2004) Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin N Am 18:569\u2013584, viii. \n                    https:\/\/doi.org\/10.1016\/j.hoc.2004.03.011","journal-title":"Hematol Oncol Clin N Am"},{"key":"2894_CR8","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE et al (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30:3486\u20133492. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.38.7522","journal-title":"J Clin Oncol"},{"key":"2894_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes JE et al (2018) Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol 36:231\u2013237. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.74.7162","journal-title":"J Clin Oncol"},{"key":"2894_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/17474086.2017.1262758","volume":"10","author":"F Marchi De","year":"2017","unstructured":"De Marchi F, Medeot M, Fanin R, Tiribelli M (2017) How could patient reported outcomes improve patient management in chronic myeloid leukemia? Expert Rev Hematol 10:9\u201314. \n                    https:\/\/doi.org\/10.1080\/17474086.2017.1262758","journal-title":"Expert Rev Hematol"},{"key":"2894_CR11","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","volume":"2016","author":"F Efficace","year":"2016","unstructured":"Efficace F, Cannella L (2016) The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematol Am Soc Hematol Educ Program 2016:170\u2013179. \n                    https:\/\/doi.org\/10.1182\/asheducation-2016.1.170","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2894_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace F et al (2014a) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23:825\u2013836. \n                    https:\/\/doi.org\/10.1007\/s11136-013-0523-5","journal-title":"Qual Life Res"},{"key":"2894_CR13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3324\/haematol.2013.093724","volume":"99","author":"F Efficace","year":"2014","unstructured":"Efficace F et al (2014b) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99:788\u2013793. \n                    https:\/\/doi.org\/10.3324\/haematol.2013.093724","journal-title":"Haematologica"},{"key":"2894_CR14","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/cncr.31323","volume":"124","author":"F Efficace","year":"2018","unstructured":"Efficace F et al (2018) Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer 124:2228\u20132237. \n                    https:\/\/doi.org\/10.1002\/cncr.31323","journal-title":"Cancer"},{"key":"2894_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, Marin D (2011) Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35:626\u2013630. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2010.10.017","journal-title":"Leuk Res"},{"key":"2894_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol","year":"1990","unstructured":"EuroQol-Group (1990) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16:199\u2013208","journal-title":"Health Policy"},{"key":"2894_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553\u2013561. \n                    https:\/\/doi.org\/10.1093\/jnci\/djr060","journal-title":"J Natl Cancer Inst"},{"key":"2894_CR18","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA et al (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 21:2138\u20132146. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.12.154","journal-title":"J Clin Oncol"},{"key":"2894_CR19","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M, European L (2007) Chronic myeloid leukaemia. Lancet 370:342\u2013350. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)61165-9","journal-title":"Lancet"},{"key":"2894_CR20","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP et al (2010) Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International randomized study of interferon and STI571 (IRIS). Blood 116:3758\u20133765. \n                    https:\/\/doi.org\/10.1182\/blood-2010-03-273979","journal-title":"Blood"},{"key":"2894_CR21","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","volume":"117","author":"AR Ibrahim","year":"2011","unstructured":"Ibrahim AR et al (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733\u20133736. \n                    https:\/\/doi.org\/10.1182\/blood-2010-10-309807","journal-title":"Blood"},{"key":"2894_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-94-007-7596-1_3","volume-title":"Self-reported population health: an international perspective based on EQ-5D","author":"B Janssen","year":"2014","unstructured":"Janssen B, Szende A (2014) Population norms for the EQ-5D. In: Szende A, Janssen B, Cabases J (eds) Self-reported population health: an international perspective based on EQ-5D. Springer, Dordrecht, pp\u00a019\u201330. \n                    https:\/\/doi.org\/10.1007\/978-94-007-7596-1_3"},{"key":"2894_CR23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","volume":"82","author":"HM Kantarjian","year":"1993","unstructured":"Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M (1993) Chronic myelogenous leukemia: a concise update. Blood 82:691\u2013703","journal-title":"Blood"},{"key":"2894_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/cncr.31082","volume":"124","author":"HM Kantarjian","year":"2018","unstructured":"Kantarjian HM et al (2018) Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer 124:587\u2013595. \n                    https:\/\/doi.org\/10.1002\/cncr.31082","journal-title":"Cancer"},{"key":"2894_CR25","doi-asserted-by":"publisher","first-page":"6612","DOI":"10.1200\/jco.2011.29.15_suppl.6612","volume":"29","author":"JH Lipton","year":"2011","unstructured":"Lipton JH et al (2011) Health-related quality of life (HRQoL) in newly diagnosed patients (pts) with chronic phase chronic myelogenous leukemia (CP CML) treated with bosutinib (BOS) or imatinib (IM). J Clin Oncol 29:6612\u20136612. \n                    https:\/\/doi.org\/10.1200\/jco.2011.29.15_suppl.6612","journal-title":"J Clin Oncol"},{"key":"2894_CR26","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381\u20132388. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.26.3087","journal-title":"J Clin Oncol"},{"key":"2894_CR27","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L et al (2009) Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401\u20135411. \n                    https:\/\/doi.org\/10.1182\/blood-2008-12-196543","journal-title":"Blood"},{"key":"2894_CR28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004. \n                    https:\/\/doi.org\/10.1056\/NEJMoa022457","journal-title":"N Engl J Med"},{"key":"2894_CR29","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1002\/cncr.28758","volume":"120","author":"T Pearman","year":"2014","unstructured":"Pearman T, Yanez B, Peipert J, Wortman K, Beaumont J, Cella D (2014) Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. Cancer 120:2902\u20132909. \n                    https:\/\/doi.org\/10.1002\/cncr.28758","journal-title":"Cancer"},{"key":"2894_CR30","volume-title":"Bosulif\u00ae (bosutinib) prescribing information","author":"Pfizer Inc","year":"2017","unstructured":"Pfizer Inc (2017) Bosulif\u00ae (bosutinib) prescribing information. Pfizer Inc, New York"},{"key":"2894_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/00019053-200725050-00002","volume":"25","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Wilke CT, Lin HW, Lloyd A (2007) Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 25:365\u2013384. \n                    https:\/\/doi.org\/10.2165\/00019053-200725050-00002","journal-title":"Pharmacoeconomics"},{"key":"2894_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3322\/caac.20004","volume":"59","author":"K Ruddy","year":"2009","unstructured":"Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59:56\u201366. \n                    https:\/\/doi.org\/10.3322\/caac.20004","journal-title":"CA Cancer J Clin"},{"key":"2894_CR33","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K et al (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2:e186\u2013e193. \n                    https:\/\/doi.org\/10.1016\/S2352-3026(15)00048-4","journal-title":"Lancet Haematol"},{"key":"2894_CR34","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","volume":"90","author":"PA Thompson","year":"2015","unstructured":"Thompson PA, Kantarjian HM, Cortes JE (2015) Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc 90:1440\u20131454. \n                    https:\/\/doi.org\/10.1016\/j.mayocp.2015.08.010","journal-title":"Mayo Clin Proc"},{"key":"2894_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","volume":"36","author":"PC Trask","year":"2012","unstructured":"Trask PC, Cella D, Besson N, Kelly V, Masszi T, Kim DW (2012) Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 36:438\u2013442. \n                    https:\/\/doi.org\/10.1016\/j.leukres.2011.10.011","journal-title":"Leuk Res"},{"key":"2894_CR36","unstructured":"van Reenan M, Oppe M (2015) EQ-5D-3L user guide, v5.1. Basic information on how to use the EQ-5D-3L instrument. EuroQol Research Foundation. \n                    https:\/\/euroqol.org\/wp-content\/uploads\/2016\/09\/EQ-5D-3L_UserGuide_2015.pdf\n                    \n                  . Accessed Mar 28 2018"},{"key":"2894_CR37","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1185\/03007995.2016.1174108","volume":"32","author":"J Whiteley","year":"2016","unstructured":"Whiteley J, Reisman A, Shapiro M, Cortes J, Cella D (2016) Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin 32:1325\u20131334. \n                    https:\/\/doi.org\/10.1185\/03007995.2016.1174108","journal-title":"Curr Med Res Opin"},{"key":"2894_CR38","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","volume":"122","author":"LA Williams","year":"2013","unstructured":"Williams LA et al (2013) Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122:641\u2013647. \n                    https:\/\/doi.org\/10.1182\/blood-2013-01-477687","journal-title":"Blood"},{"key":"2894_CR39","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1002\/cam4.1808","volume":"7","author":"A Zulbaran-Rojas","year":"2018","unstructured":"Zulbaran-Rojas A et al (2018) A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med 7:5457\u20135469. \n                    https:\/\/doi.org\/10.1002\/cam4.1808","journal-title":"Cancer Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-02894-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T19:13:54Z","timestamp":1586805234000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-02894-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2894"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-02894-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]},"assertion":[{"value":"19 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JEC: consultancy (ARIAD, Bristol-Myers Squibb, ImmunoGen, Novartis, Pfizer, Takeda) and research funding (ARIAD, Bristol-Myers Squibb, ImmunoGen, Novartis, Sun Pharma, Pfizer, Takeda, Teva). CG-P: consultancy (Bristol-Myers Squibb) and honoraria and research funding (Pfizer). MWD: advisory board (Blue Print, Pfizer, Ascentage Pharma, and Humana), consultancy (Blue Print, Pfizer, Ascentage Pharma, and TRM), research funding (Pfizer), and study management committee (Blue Print and Takeda). MJM: consultancy (Bristol-Myers Squibb). CC: honoraria (Bristol-Myers Squibb, Chiltern, Novartis, and Otsuka) and travel (Pfizer). D-WK: consultancy (Bristol-Myers Squibb, Il-Yang, Novartis), honoraria, and research funding (Bristol-Myers Squibb, Il-Yang, Novartis, Pfizer), membership on board of directors or advisory committees (Bristol-Myers Squibb), and speakers bureau (Bristol-Myers Squibb, Novartis, Pfizer). DM: consultancy and honoraria (ARIAD, Bristol-Myers Squibb, Novartis, Pfizer) and honoraria and speakers bureau (Incyte). PlC: honoraria (ARIAD, Bristol-Myers Squibb, Incyte, Novartis, Pfizer) and research funding (Novartis). VG-G: consultancy, honoraria, and research funding (Bristol-Myers Squibb, Incyte, Novartis, Pfizer). RC: equity ownership (Pfizer and GlaxoSmithKline). CM: employment and equity ownership (Pfizer). AR: employment (Pfizer). AH: research funding (Bristol-Myers Squibb, Incyte, Novartis, Pfizer). THB: consultancy (Novartis, Pfizer, Janssen, Merck, Takeda) and research funding (Novartis, Pfizer).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}